Discontinued — last reported Q2 '23
D.R. Horton Acquisitions decreased by 92.9% to $5.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 176.2%, from $2.10M to $5.80M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 21.3% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $200.00K | $100.00K | $0.00 | $0.00 | $271.50M | $0.00 | $97.10M | $6.40M | $98.50M | $10.90M | $1.00M | $0.00 | $36.90M | $2.50M | $51.00M | $2.10M | $0.00 | $0.00 | $82.10M | $5.80M |
| QoQ Change | — | -50.0% | -100.0% | — | — | -100.0% | — | -93.4% | >999% | -88.9% | -90.8% | -100.0% | — | -93.2% | >999% | -95.9% | -100.0% | — | — | -92.9% |
| YoY Change | — | — | — | — | >999% | -100.0% | — | — | -63.7% | — | -99.0% | -100.0% | -62.5% | -77.1% | >999% | — | -100.0% | -100.0% | +61.0% | +176.2% |